GlassScriptPhysician profile
Brandon Reece Hull
NPI 1851703953
$66,649.46
in general payments reported to CMS, 2019-2025
28 companies · $20K in 2025
The $20K reported for 2025 was more than what 91% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $2,094 · 2021: $1,589 · 2022: $4,501 · 2023: $17K · 2024: $21K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $31K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $6,271 · Travel and Lodging: $4,822 · Honoraria: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,282.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,796.88 |
| Food and Beverage | $6,271.25 |
| Travel and Lodging | $4,822.37 |
| Honoraria | $2,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $56,428.46 | 2019-2025 | Evos, Trigen Intertan, Evos Mini |
| Illuminoss Medical, INC. | $2,496.64 | 2024-2025 | |
| Stryker Corporation | $1,832.90 | 2019-2025 | T2, Na, Gamma |
| Synthes Gmbh | $1,476.19 | 2020 | |
| US Implant Solutions, LLC | $1,205.25 | 2024-2025 | |
| Curvafix, INC. | $1,075.57 | 2025 | Curvafix Im Implant |
| Acera Surgical, INC. | $765.90 | 2022-2025 | Restrata Wound Matrix |
| Medical Device Business Services, INC. | $250.00 | 2019 | |
| Si-Bone, INC. | $200.05 | 2022 | |
| Acell, INC. | $148.48 | 2019 | |
| Pylant Medical | $113.55 | 2020-2021 | |
| Musculoskeletal Transplant Foundation INC. | $100.37 | 2019 | |
| Kci USA, INC. | $91.87 | 2021-2023 | Prevena, V.A.C.Ulta, V.A.C. Veraflo |
| P Bar Medical LLC | $70.70 | 2025 | |
| Biocomposites INC | $62.70 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $60.47 | 2025 | V.A.C. Veraflo Cleanse Choice, V.A.C.Ulta, Prevena |
| Banner Life Sciences, LLC | $33.79 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $31.64 | 2023 | Iovera |
| Polynovo North America LLC | $28.62 | 2025 | Novosorb Btm |
| Kerecis Limited | $28.30 | 2021 | |
| Avita Medical Americas, LLC | $26.98 | 2024 | |
| Innovation Technologies INC | $24.74 | 2025 | Irrisept |
| Bioventus LLC | $22.88 | 2025 | Exogen Ultrasound Bone Healing System |
| Organogenesis INC. | $19.26 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $16.39 | 2025 | |
| Orthofix Medical, INC. | $15.31 | 2023 | Spinal-Stim, Physio-Stim, Cervical-Stim |
| Convatec INC. | $14.85 | 2021 | |
| Depuy Synthes Sales INC. | $7.60 | 2024 | Na |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.